Because opioid receptors have been reported on cancer cells we examined whether peptides synthesized in our lab could decrease the proliferation of prostate cancer cells. Both the macrocyclic tetrapeptides CJ-15,208 and [D-Trp]CJ-15,208 exhibited antiproliferative activity in these cells which appears to involve degradation of the oncoprotein c-Myc. Current studies are further exploring the mechanism of action of the peptides, particularly their effects on proteins in the c-Myc degradation pathway, and examining their SAR for anticancer activity with the goal of improving potency. We are also examining the peptides’ antiproliferative effects in vivo and in other cancers.
- Mukhopadhyay, L.E. Hanold, H. Thayele Purayil, S. Gisemba, S. Sanadheera, J.V. Aldrich. Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth. Cancer Biol Ther. 2017, 18, 571-583. https://www.ncbi.nlm.nih.gov/pubmed/28692379